✦ LIBER ✦

FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials

✍ Scribed by Petrelli, Fausto; Borgonovo, Karen; Cabiddu, Mary; Ghilardi, Mara; Lonati, Veronica; Maspero, Federica; Sauta, Maria Grazia; Beretta, Giordano Domenico; Barni, Sandro

Book ID: 122849464
Publisher: CIG Media Group, LP.
Year: 2013
Tongue: English
Weight: 904 KB
Volume: 12
Category: Article
ISSN: 1533-0028
DOI: 10.1016/j.clcc.2013.04.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

KRAS as prognostic biomarker in metastat

KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials

✍ Petrelli, Fausto; Coinu, Andrea; Cabiddu, Mary; Ghilardi, Mara; Barni, Sandro 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 747 KB

Effects of bevacizumab on plasma concent

Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy

✍ Yosuke Horita; Y. Yamada; Y. Hirashima; K. Kato; T. Nakajima; T. Hamaguchi; Y. S 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 529 KB

XELIRI-bevacizumab versus FOLFIRI-bevaci

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

✍ Dimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, Anastasia G El 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 286 KB

Addition of bevacizumab to first-line ch

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups

✍ Ligia Traldi Macedo, Andre Bacellar da Costa Lima, Andre Deeke Sasse 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 439 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

✍ Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Jage 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 225 KB

The efficacy and safety of bevacizumab b

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)

✍ Goro Nakayama, Keisuke Uehara, Kiyoshi Ishigure… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 352 KB